Agenus Inc. (NASDAQ:AGEN – Get Free Report) was the target of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 2,240,000 shares, a decrease of 17.9% from the May 31st total of 2,730,000 shares. Based on an average trading volume of 803,700 shares, the short-interest ratio is currently 2.8 days. Approximately 11.2% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on AGEN. StockNews.com assumed coverage on Agenus in a report on Wednesday, April 17th. They issued a “hold” rating on the stock. B. Riley dropped their target price on Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, March 18th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Agenus in a report on Friday.
Read Our Latest Stock Analysis on Agenus
Agenus Stock Down 14.4 %
Agenus (NASDAQ:AGEN – Get Free Report) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.54. The firm had revenue of $28.01 million during the quarter, compared to analysts’ expectations of $40.70 million. On average, sell-side analysts forecast that Agenus will post -9.7 earnings per share for the current year.
Institutional Trading of Agenus
A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Agenus by 3,008.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company’s stock worth $1,909,000 after purchasing an additional 2,232,064 shares during the last quarter. Readystate Asset Management LP lifted its stake in shares of Agenus by 14.3% in the 4th quarter. Readystate Asset Management LP now owns 2,016,783 shares of the biotechnology company’s stock valued at $1,670,000 after acquiring an additional 252,124 shares during the last quarter. Cardinal Strategic Wealth Guidance lifted its stake in shares of Agenus by 28.2% in the 4th quarter. Cardinal Strategic Wealth Guidance now owns 910,265 shares of the biotechnology company’s stock valued at $754,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its stake in shares of Agenus by 38.0% in the 1st quarter. Key Client Fiduciary Advisors LLC now owns 858,969 shares of the biotechnology company’s stock valued at $498,000 after acquiring an additional 236,500 shares during the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.
About Agenus
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
- Five stocks we like better than Agenus
- 3 Ways To Invest In Coffee, Other Than Drinking It
- RXO Shares Surge Following New Acquisition Deal
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.